BIRMINGHAM, Ala., April 28, 2025 /PRNewswire/ -- Encompass Health Corp. (NYSE: EHC) today announced it will participate in the BofA Securities 2025 Healthcare Conference, which is being held May 13-15, 2025.
Encompass Health's Executive Vice President and Chief Financial Officer Doug Coltharp will participate in a fireside chat on Tuesday, May 13, 2025, from 8:40-9:10 a.m. PT.
The presentation will be webcast live and available at investor.encompasshealth.com.
About Encompass Health
Encompass Health (NYSE: EHC) is the largest owner and operator of inpatient rehabilitation hospitals in the United States. With a national footprint that includes 167 hospitals in 38 states and Puerto Rico, the Company provides high-quality, compassionate rehabilitative care for patients recovering from a major injury or illness, using advanced technology and innovative treatments to maximize recovery. Encompass Health is ranked as one of Fortune's World's Most Admired Companies™, Becker's Hospital Review's 150 Top Places to Work in Healthcare and Forbes' Most Trusted Companies in America. For more information, visit encompasshealth.com, or follow us on our newsroom, X, Instagram and Facebook.
From Fortune. © 2025 Fortune Media IP Limited. All rights reserved. Fortune® is a registered trademark and Fortune World's Most Admired Companies™ is trademark of Fortune Media IP Limited and are used under license. Fortune and Fortune Media IP Limited are not affiliated with, and do not endorse products or services of, Encompass Health. From Forbes © 2024 Forbes Media LLC. All rights reserved. Used under license.
Media contact:
Polly Manuel | 205-970-5912
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Relations contact:
Mark Miller | 205-970-5860
This email address is being protected from spambots. You need JavaScript enabled to view it.
Last Trade: | US$116.41 |
Daily Change: | 0.50 0.43 |
Daily Volume: | 608,460 |
Market Cap: | US$11.730B |
April 24, 2025 April 24, 2025 December 18, 2024 November 04, 2024 |
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MOREClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREEnd of content
No more pages to load